Venus Remedies Ltd

NSE: VENUSREM · BSE: 526953 · Pharmaceuticals & Biotechnology · 21 announcements

Share price: ₹1,769.40
Market cap: ₹2,365 Cr
Revenue (annual): ₹769.6 Cr
Net profit (annual): ₹102.8 Cr
P/E (TTM): 20.4×Sector 47.3×
Promoter holding: 41.76%+0.00% QoQ
FII holding: 2.92%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 8 Financial Results 4 Management Change 2 Annual General Meeting 2 Regulatory Approval 1 Dividend 1 Business Update 1 Board Meeting Outcome 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

4 announcements with these filters

20 Jul 2026 18:34 IST BSE

Financial Results

Venus Remedies Q1 FY27 Results: Net Profit ₹23 Cr, Up 139.6% YoY

Venus Remedies Ltd reported revenue from operations of ₹178.9 Cr (+30.4% YoY) and net profit of ₹23 Cr (+139.6% YoY) for Q1 FY27.

Key figure: Net profit ₹23 Cr · +139.6% YoY

Open full results → Read the filing ↗

26 May 2026 21:54 IST BSE

Financial ResultsAlfa Alert

Venus Remedies Q4 FY26 Results: Net Profit ₹47.5 Cr, Up 126.2% YoY

Venus Remedies Ltd reported revenue from operations of ₹259.4 Cr (+31.2% YoY) and net profit of ₹47.5 Cr (+126.2% YoY) for Q4 FY26.

Key figure: Net profit ₹47.5 Cr · +126.2% YoY

Open full results → Read the filing ↗

26 May 2026 21:53 IST BSE

Financial Results

Venus Remedies Financial Results

Venus Remedies reported annual consolidated total income of ₹782.18 Crore and net profit of ₹102.78 Crore. The board recommended a 100% final dividend of ₹10 per share.

Value: ₹782.2 Cr

Read the filing ↗

8 Apr 2026 22:25 IST BSE

Financial Results

Venus Remedies Q3 FY26 Results: Net Profit ₹25.6 Cr, Up 30.6% YoY

Venus Remedies Ltd reported net profit of ₹25.6 Cr (+30.6% YoY) for Q3 FY26.

Key figure: Net profit ₹25.6 Cr · +30.6% YoY

Open full results → Read the filing ↗